Featured project: Exploring Statin Pleiotropic Effects within a Very Large EHR Cohort
Statins (HMG-CoA reductase inhibitors), among the most widely prescribed agents worldwide for prevention of cardiovascular diseases, produce substantial pleiotropic effects. Pleiotropic effects are unanticipated outcomes other than those for which the drug was originally developed, either therapeutic (beneficial) or detrimental (adverse drug reactions). Statin pleiotropic effects are unanticipatedly broad, including increasing the risk of developing type 2 diabetes mellitus (T2DM), decreasing cancer-related mortality, and reducing dementia. Many effects are still not determined. In addition, individual responses to statins are highly variable. In this project, we investigate statin pleiotropic effects using whole de-identified electronic health records (EHRs) of >2.5 million patients at Vanderbilt, including >100,000 statin recipients. We will evaluate genetic predictors of statin pleiotropic effects as well.
PGRN Hub & the Featured Investigator